RavenQuest BioMed Inc.
RVVQF · OTC
7/31/2019 | 4/30/2019 | 1/31/2019 | 10/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.62 | 3.37 | 0.07 | -0.00 |
| FCF Yield | -4.41% | -3.11% | -0.20% | -4.66% |
| EV / EBITDA | -43.30 | -46.25 | -55.37 | -4.21 |
| Quality | ||||
| ROIC | -7.80% | -6.42% | -6.92% | -30.06% |
| Gross Margin | 62.40% | -20.05% | -54.99% | 130.50% |
| Cash Conversion Ratio | 0.46 | 0.27 | -0.48 | 0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,150,161.31% | 994,579.41% | 981,304.00% | 1,079,012.21% |
| Free Cash Flow Growth | 11.90% | -1,463.30% | 95.64% | 70.11% |
| Safety | ||||
| Net Debt / EBITDA | -9.87 | -7.23 | -8.33 | -0.62 |
| Interest Coverage | -3.06 | -2.52 | -3.11 | -14.57 |
| Efficiency | ||||
| Inventory Turnover | 0.98 | 5.68 | -2.52 | 0.05 |
| Cash Conversion Cycle | 207.58 | 59.59 | 402.66 | -3,050.61 |